Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7OE3X)

Drug Name

INCAGN1949 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting OX40L receptor (CD134)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rocatinlimab	DMG1U5K	Atopic dermatitis	EA80	Phase 3	[2]
GBR 830	DM2VO9T	Atopic dermatitis	EA80	Phase 2	[3]
PF-04518600	DMZMUIL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
INCAGN01949	DMK7OHI	Advanced malignancy	2A00-2F9Z	Phase 2	[5]
TAK-252	DM1AKNI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
Anti-OX40 mab	DMFZ52G	Prostate cancer	2C82.0	Phase 1	[7]
MEDI0562	DMYVBU6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
BGB-A445	DMQMEDH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
YH002	DMWVRHD	Aggressive cancer	2A00-2F9Z	Phase 1	[9]
YH006	DMRECC2	Aggressive cancer	2A00-2F9Z	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023 Jan 21;401(10372):204-214.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol Oncol Rep. 2020 Oct 1;34:100655.
6	Clinical pipeline report, company report or official report of Shattuck Labs.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1873).
8	Clinical pipeline report, company report or official report of BeiGene.
9	Clinical pipeline report, company report or official report of Biocytogen
10	Clinical pipeline report, company report or official report of Biocytogen